111 Capital Takes $776,000 Position in Qiagen N.V. $QGEN

111 Capital bought a new position in shares of Qiagen N.V. (NYSE:QGEN) during the fourth quarter, HoldingsChannel reports. The fund bought 16,967 shares of the company’s stock, valued at approximately $776,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Barclays PLC raised its stake in Qiagen by 14.3% in the third quarter. Barclays PLC now owns 1,086,931 shares of the company’s stock valued at $48,564,000 after buying an additional 135,638 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Qiagen by 10.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 3,164,805 shares of the company’s stock worth $143,018,000 after buying an additional 290,449 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Qiagen by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 9,542,944 shares of the company’s stock worth $433,871,000 after buying an additional 118,135 shares during the last quarter. Moors & Cabot Inc. grew its holdings in shares of Qiagen by 78.2% during the third quarter. Moors & Cabot Inc. now owns 352,809 shares of the company’s stock worth $15,764,000 after buying an additional 154,851 shares during the last quarter. Finally, Jefferies Financial Group Inc. purchased a new stake in Qiagen in the 3rd quarter valued at approximately $3,025,000. Institutional investors own 70.00% of the company’s stock.

Analyst Upgrades and Downgrades

QGEN has been the topic of several research analyst reports. Barclays set a $38.00 price target on Qiagen and gave the stock an “equal weight” rating in a research note on Wednesday, April 29th. TD Cowen reiterated a “hold” rating and issued a $40.00 price target (down from $46.00) on shares of Qiagen in a report on Thursday, May 7th. Robert W. Baird set a $43.00 price target on Qiagen and gave the company an “outperform” rating in a report on Wednesday, April 29th. UBS Group set a $52.00 price target on Qiagen in a report on Monday, February 9th. Finally, Wall Street Zen downgraded Qiagen from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Qiagen has an average rating of “Hold” and an average price target of $44.98.

Qiagen Stock Down 2.3%

Shares of NYSE QGEN opened at $36.69 on Friday. Qiagen N.V. has a 12-month low of $32.53 and a 12-month high of $57.81. The company has a market cap of $7.56 billion, a P/E ratio of 19.16, a P/E/G ratio of 3.74 and a beta of 0.66. The company has a current ratio of 3.21, a quick ratio of 2.57 and a debt-to-equity ratio of 0.49. The stock has a fifty day moving average price of $37.33 and a 200 day moving average price of $44.40.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.54 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.54. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.The firm had revenue of $492.32 million during the quarter, compared to the consensus estimate of $496.15 million. During the same period in the prior year, the firm earned $0.56 EPS. Research analysts anticipate that Qiagen N.V. will post 2.43 EPS for the current fiscal year.

Qiagen Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Tuesday, July 14th. Stockholders of record on Tuesday, July 7th will be paid a dividend of $0.35 per share. This is a boost from Qiagen’s previous annual dividend of $0.26. This represents a dividend yield of 104.0%. The ex-dividend date is Tuesday, July 7th. Qiagen’s payout ratio is 13.61%.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.